Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48-Week, Study of Oral Recombinant Salmon Calcitonin (rsCT) Compared to Salmon Calcitonin (sCT) Nasal Spray in Postmenopausal Osteoporotic Women

NCT00959764 is registered in ClinicalTrials.gov with Tarsa Therapeutics, Inc. as lead sponsor.

NCT NCT00959764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00959764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multiple Dose, Placebo-Controlled, Parallel Group, 48-Week, Study of Oral Recombinant Salmon Calcitonin (rsCT) Compared to Salmon Calcitonin (sCT) Nasal Spray in Postmenopausal Osteoporotic Women
Lead sponsor
Tarsa Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2009
Completion date
February 28, 2011
Enrollment
565 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis, postmenopausal